*December 2019* With the inevitability of resistance to first- and second-generation EGFR tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutant non–small
About firstname.lastname@example.orgThis author has not yet filled in any details.
So far email@example.com has created 40 blog entries.
Bridge Biotherapeutics Files Investigational New Drug Application for BBT-176, an EGFR TKI for NSCLClaurabbook@gmail.com2020-01-18T15:58:59-08:00
*December 2019* SEONGNAM, South Korea, Dec. 19, 2019 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea, announced that
*December 2019* Adding chemotherapy to a targeted agent doubled progression-free survival (PFS) for patients with advanced EGFR-mutant non-small cell lung
*December 2019* Patients with EGFR-mutant (m) non-small-cell lung cancer (NSCLC) and leptomeningeal metastases (LM) respond favorably to high daily doses of
*January 2020* Dana-Farber Cancer Institute will create the Chen-Huang Center for EGFR (epidermal growth factor receptor) Mutant Lung Cancers to
*December 2019* Project PRIORITY (Patient Reported Initiative On Resistance, Incidence, Treatment studY), is a collaboration between LUNGevity Foundation and the EGFR
*November 2019* Jill Feldman, an EGFR Resisters co-founder was interviewed on the Today Show regarding Lung Cancer Awareness Month. Watch
*November 2019* Phase II progression on any TKI with a new 3rd generation TKI, lazertinib. Location: Montefiore/Einstein in NYC. More
*October 2019* Presented by EGFR Resisters Co-Founders. * Hospitalization - While TKIs are superior to other treatments for EGFR positive lung
*September 2019* by Dr. Mark Kris for Medscape This is Mark Kris from Memorial Sloan Kettering. Just when we thought